Identification of deregulation in protein expression level of erlotinib-resistant A549 cell lines
Despite modern advancements in surgeries, chemotherapies, and radiotherapies over the past few years, lung cancer still remains a very difficult disease to treat. This has left the death rate from lung cancer victims largely unchanged throughout the past few decades. A key cause for the high m...
Saved in:
| Main Author: | |
|---|---|
| Format: | Project Paper Report |
| Language: | English |
| Published: |
2015
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/85052/1/FBSB%202015%20118%20-%20IR.pdf http://psasir.upm.edu.my/id/eprint/85052/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Despite modern advancements in surgeries, chemotherapies, and radiotherapies over
the past few years, lung cancer still remains a very difficult disease to treat. This has left the
death rate from lung cancer victims largely unchanged throughout the past few decades. A key cause
for the high mortality rate is the drug resistance that builds up for patients being currently
treated with the chemotherapeutic agents. Erlotinib is found to be an effective drug in
treating the non-small cell lung cancer (NSCLC). However, development of resistance towards
this drug has become one of the major clinical problems. Development of cell resistance is
hypothesized to involve in deregulation of protein expression in the cell cycle. Two cell lines
namely A549 and A549R (erlotinib-resistant A549) were used to compare and contrast the
level of these protein expression in the cell cycle. This will provide supporting information on
the development of erlotinib-resistant NSCLC. In this experiment, the optimization
of total protein lysate required was conducted to observe differences in protein expression of
selected cell cycles payers such as cyclin A, cyclin E, cyclin D, CDK4, CDK6, NF-κB and
p-21. The result shows protein expression of cyclin A could be differentiate if the
total lysate of 100µg protein were used. Therefore, a better understanding of the
characterization and mechanism of resistance to erlotinib in A549R cells is important in the
identification of agents that could reverse clinical
erlotinib resistance in NSCLC. |
|---|